{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:28:12Z","timestamp":1790015292214,"version":"4.0.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011619","name":"Society for Immunotherapy of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102881","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:38:58Z","timestamp":1782398338000},"page":"102881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-7102","authenticated-orcid":false,"given":"Gohar Shahwar","family":"Manzar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Faqrul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tiberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum Puebla","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafet","family":"Basar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102881_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102881_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.xcrm.2026.102881_bib3","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102881_bib4","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231222","article-title":"Five decades of natural killer cell discovery","volume":"221","author":"Lanier","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102881_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.2009.07667.x","article-title":"Replicative potential of human natural killer cells","volume":"145","author":"Fujisaki","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2026.102881_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102881_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2026.102881_bib12","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/2326-6066.CIR-23-0151","article-title":"Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function","volume":"11","author":"Zhang","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584099","article-title":"Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102881_bib15","article-title":"GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xcrm.2026.102881_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13238-019-00665-x","article-title":"Functions of p53 in pluripotent stem cells","volume":"11","author":"Fu","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.xcrm.2026.102881_bib19","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00262-021-02975-8","article-title":"Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors","volume":"70","author":"Khodayari","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102881_bib20","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2018.02873","article-title":"Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells","volume":"9","author":"Snyder","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib21","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102881_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102881_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcyt.2020.05.001","article-title":"Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation","volume":"22","author":"Damodharan","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2026.102881_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40425-019-0652-7","article-title":"IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib25","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib26","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1615\/CritRevOncog.2014010931","article-title":"Clinical grade purification and expansion of natural killer cells","volume":"19","author":"Lapteva","year":"2014","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.xcrm.2026.102881_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383281","article-title":"PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival","volume":"15","author":"Oyer","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy","volume":"13","author":"Fern\u00e1ndez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102881_bib30","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","article-title":"Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells","volume":"11","author":"Mark","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102881_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nri2381","article-title":"Formation and function of the lytic NK-cell immunological synapse","volume":"8","author":"Orange","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari de Andrade","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102881_bib33","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","article-title":"Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation","volume":"15","author":"Berjis","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102881_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2014.01.017","article-title":"Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays","volume":"406","author":"Mata","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.xcrm.2026.102881_bib35","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2014-11-610311","article-title":"CD56(dim)CD16(-) NK cell phenotype can be induced by cryopreservation","volume":"125","author":"Lugthart","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2026.102881_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902938","article-title":"Nanoparticle-Mediated Intracellular Protection of Natural Killer Cells Avoids Cryoinjury and Retains Potent Antitumor Functions","volume":"7","author":"Yao","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2026.102881_bib38","article-title":"Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing","volume":"19","author":"Lee","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102881_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcyt.2016.02.008","article-title":"Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells","volume":"18","author":"Domogala","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2026.102881_bib40","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","article-title":"Generation of \u201cOff-the-Shelf\u201d Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells","volume":"9","author":"Zeng","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102881_bib41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/imcb.12820","article-title":"A scalable, spin-free approach to generate enhanced induced pluripotent stem cell-derived natural killer cells for cancer immunotherapy","volume":"102","author":"Rossi","year":"2024","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102881_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib43","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/bloodadvances.2023012463","article-title":"Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy","volume":"8","author":"Han","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102881_bib44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib45","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current Perspectives on \u201cOff-The-Shelf\u201d Allogeneic NK and CAR-NK Cell Therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(86)91705-8","article-title":"Heat treatment of factor VIII concentrate","volume":"327","author":"Rousell","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102881_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102881_bib49","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK Cells in the Treatment of Solid Tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102881_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib51","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib52","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102881_bib54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","article-title":"NK cells are never alone: crosstalk and communication in tumour microenvironments","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib55","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102881_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.ATV.21.2.227","article-title":"Induction of endothelial-leukocyte interaction by interferon-gamma requires coactivation of nuclear factor-kappaB","volume":"21","author":"De Caterina","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.xcrm.2026.102881_bib57","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming","volume":"5","author":"Mart\u00edn-Fontecha","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib58","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/eji.201444497","article-title":"IFN-gamma regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1","volume":"44","author":"Medina-Echeverz","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ebiom.2018.02.009","article-title":"Interferon Gamma Induces Reversible Metabolic Reprogramming of M1 Macrophages to Sustain Cell Viability and Pro-Inflammatory Activity","volume":"30","author":"Wang","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2026.102881_bib60","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2004-10-4035","article-title":"NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor","volume":"106","author":"Vitale","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2007.03.006","article-title":"Dendritic cells prime natural killer cells by trans-presenting interleukin 15","volume":"26","author":"Lucas","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102881_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102881_bib64","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102881_bib65","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102881_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102881_bib67","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/0008-5472.CAN-08-3126","article-title":"Natural killer cells require selectins for suppression of subcutaneous tumors","volume":"69","author":"Sobolev","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib68","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102881_bib69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fimmu.2016.00402","article-title":"Dysregulation of Chemokine\/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases","volume":"7","author":"Bernardini","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib70","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An Oncolytic Virus Expressing IL15\/IL15Ralpha Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2026.102881_bib72","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102881_bib73","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/jcrt.JCRT_190_20","article-title":"Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis","volume":"16","author":"Li","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.xcrm.2026.102881_bib74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy","volume":"6","author":"Henke","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.xcrm.2026.102881_bib75","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","article-title":"Role of Matrix Metalloproteinases in Angiogenesis and Cancer","volume":"9","author":"Quintero-Fabi\u00e1n","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102881_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117487","article-title":"ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders","volume":"548","author":"Singh","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.xcrm.2026.102881_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.trecan.2023.04.004","article-title":"The peritumor microenvironment: physics and immunity","volume":"9","author":"Zhang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib78","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4598476","article-title":"Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways","volume":"2020","author":"Teng","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib79","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/eji.201343448","article-title":"Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC","volume":"43","author":"Balsamo","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib80","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1304790110","article-title":"Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia","volume":"110","author":"Baginska","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102881_bib81","doi-asserted-by":"crossref","first-page":"11448","DOI":"10.1021\/acs.jmedchem.0c00525","article-title":"Discovery of AB680: A Potent and Selective Inhibitor of CD73","volume":"63","author":"Lawson","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102881_bib82","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/2326-6066.CIR-18-0481","article-title":"Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis","volume":"7","author":"Harmon","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib83","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","article-title":"Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment","volume":"33","author":"Poznanski","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102881_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2026.102881_bib85","article-title":"Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models","volume":"13","author":"Otegbeye","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102881_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142116","article-title":"Targeting the alphav integrin\/TGF-beta axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102881_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp0004","article-title":"BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML","volume":"16","author":"Kumar","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib88","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3389\/fimmu.2018.01859","article-title":"Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation","volume":"9","author":"Park","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib89","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/cancers14041078","article-title":"Knowns and Unknowns about CAR-T Cell Dysfunction","volume":"14","author":"Titov","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102881_bib90","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib91","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73699","article-title":"Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors","volume":"11","author":"Chambers","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2026.102881_bib92","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","article-title":"mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function","volume":"193","author":"Donnelly","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102881_bib94","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib95","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","article-title":"CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells","volume":"643","author":"Rafei","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102881_bib96","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3838","article-title":"Srebp-controlled glucose metabolism is essential for NK cell functional responses","volume":"18","author":"Assmann","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib97","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3892\/ol.2015.3545","article-title":"Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation","volume":"10","author":"Abd-Aziz","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.xcrm.2026.102881_bib98","doi-asserted-by":"crossref","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib99","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood-2024-204369","article-title":"Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia","volume":"144","author":"Jang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102881_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn0881","article-title":"CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer","volume":"10","author":"Tarannum","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102881_bib102","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102881_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002044","article-title":"TGFbeta drives NK cell metabolic dysfunction in human metastatic breast cancer","volume":"9","author":"Slattery","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib104","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2015.327","article-title":"The TGF-beta\/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia","volume":"30","author":"Rouce","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2026.102881_bib105","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","article-title":"Disruption of TGF-beta signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells","volume":"31","author":"Thangaraj","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102881_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122888","article-title":"An innovative strategy harnessing self-activating CAR-NK cells to mitigate TGF-beta1-driven immune suppression","volume":"314","author":"Shin","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.xcrm.2026.102881_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102712","article-title":"TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies","volume":"15","author":"Hasan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102881_bib108","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib109","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102881_bib110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12\/SDF-1alpha-secreting Glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102881_bib111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102881_bib112","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1136\/jitc-2019-000131","article-title":"CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency","volume":"8","author":"Li","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib113","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107507118","article-title":"Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102881_bib114","article-title":"CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102881_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add1187","article-title":"Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102881_bib116","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.21873\/anticanres.13796","article-title":"Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of (125)I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma","volume":"39","author":"Xia","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib117","doi-asserted-by":"crossref","first-page":"e011330","DOI":"10.1136\/jitc-2024-011330","article-title":"Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy","volume":"13","author":"Reindl","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib118","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1089\/hum.2017.168","article-title":"Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy","volume":"28","author":"Klapdor","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102881_bib119","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4263520","article-title":"Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7150\/ijbs.65019","article-title":"Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer","volume":"18","author":"Yan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.xcrm.2026.102881_bib121","first-page":"1","article-title":"Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma","volume":"2017","author":"Zhang","year":"2017","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib122","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102881_bib123","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","article-title":"Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102881_bib124","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102881_bib125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.omtm.2022.10.010","article-title":"Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-beta","volume":"27","author":"Chaudhry","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102881_bib126","doi-asserted-by":"crossref","first-page":"e003050","DOI":"10.1136\/jitc-2021-003050","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors","volume":"9","author":"Jan","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib127","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noy139.255","article-title":"Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity","volume":"20","author":"Strassheimer","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102881_bib128","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2127508","article-title":"AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma","volume":"11","author":"Strecker","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xcrm.2026.102881_bib129","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xcrm.2026.102881_bib130","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CJI.0000000000000286","article-title":"Anti-alphaFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against alphaFR-positive Ovarian Cancer","volume":"42","author":"Ao","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102881_bib131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102881_bib132","article-title":"Fate Therapeutics Announces FDA Clearance for FT536, a First-In-Class MICA\/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors","author":"Tartaglia","year":"2022","journal-title":"Fate Therapeutics News Releases, ir.fatetherapeutics.com\/news-releases"},{"key":"10.1016\/j.xcrm.2026.102881_bib133","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells","volume":"8","author":"Ferrari de Andrade","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib134","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2020.07.016","article-title":"Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment","volume":"326","author":"Lee","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.xcrm.2026.102881_bib135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.surg.2019.05.047","article-title":"Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty\/minicircle vector into NK-92MI cells for treatment of pancreatic cancer","volume":"166","author":"Batchu","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.xcrm.2026.102881_bib136","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xcrm.2026.102881_bib137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12865-018-0262-z","article-title":"Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells","volume":"19","author":"Shiozawa","year":"2018","journal-title":"BMC Immunol."},{"key":"10.1016\/j.xcrm.2026.102881_bib138","first-page":"2823","article-title":"Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.xcrm.2026.102881_bib139","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102881_bib140","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.xcrm.2026.102881_bib141","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102881_bib142","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.xcrm.2026.102881_bib143","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221094244","article-title":"Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell Transplant."},{"key":"10.1016\/j.xcrm.2026.102881_bib144","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102881_bib145","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.xcrm.2026.102881_bib146","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102881_bib147","doi-asserted-by":"crossref","first-page":"e004306","DOI":"10.1136\/jitc-2021-004306","article-title":"Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade","volume":"10","author":"Patin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib148","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102881_bib149","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102881_bib150","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood-2012-07-442558","article-title":"Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production","volume":"121","author":"Chiang","year":"2013","journal-title":"Blood"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:04:32Z","timestamp":1784750672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":150,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126002983"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102881","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102881"}}